​

Kezar Life Sciences (KZR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

KZR Stock Forecast

Kezar Life Sciences (KZR) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $9.00 and a low of $9.00. This represents a 87.89% increase from the last price of $4.79.

- $1 $2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $9 Low: $9 Last Closed Price: $4.79

KZR Stock Rating

Kezar Life Sciences stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (50.00%), 3 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 3 3 Strong Sell Sell Hold Buy Strong Buy

KZR Price Target Upside V Benchmarks

TypeNameUpside
StockKezar Life Sciences87.89%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$9.00
Last Closing Price$4.79$4.79$4.79
Upside/Downside--87.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-33--6
May, 25-33--6
Apr, 25-33--6
Mar, 25-33--6
Feb, 25-24--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 19, 2024Derek ArchilaWells Fargo$9.00$6.2643.77%87.89%
Aug 12, 2022H.C. Wainwright$21.00$9.76115.16%338.41%
May 04, 2022Wells Fargo$14.00$7.9476.32%192.28%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024H.C. WainwrightNeutralNeutralhold
Oct 14, 2024H.C. WainwrightNeutralNeutralhold
Oct 02, 2024H.C. WainwrightNeutraldowngrade
Oct 01, 2024Cowen & Co.BuyBuyhold
Aug 14, 2024Cowen & Co.BuyBuyhold
Jan 03, 2023Wells FargoOverweightOverweighthold
Jun 28, 2022Wells FargoOverweightOverweighthold

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.40$-1.15----
Avg Forecast$-13.56$-5.77$-8.52$-7.02$-7.86$-6.26
High Forecast$-12.87$-2.65$-3.60$-3.65$-3.42$-6.26
Low Forecast$-14.45$-14.91$-11.34$-11.86$-15.26$-6.26
Surprise %-89.68%-80.07%----

Revenue Forecast

$0 $7M $14M $21M $28M $35M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.00M-----
Avg Forecast$7.00M$2.40M$4.00M$7.00M$21.00M$31.50M
High Forecast$7.00M$2.40M$4.00M$7.00M$21.00M$31.50M
Low Forecast$7.00M$2.40M$4.00M$7.00M$21.00M$31.50M
Surprise %------

Net Income Forecast

$-2B $-1B $-900M $-600M $-300M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-101.87M$-83.74M----
Avg Forecast$-990.92M$-637.14M$-541.94M$-562.74M$-677.60M$-453.82M
High Forecast$-933.48M$-192.52M$-261.11M$-264.86M$-248.28M$-453.82M
Low Forecast$-1.05B$-1.08B$-822.76M$-860.62M$-1.11B$-453.82M
Surprise %-89.72%-86.86%----

KZR Forecast FAQ

Is Kezar Life Sciences stock a buy?

Kezar Life Sciences stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kezar Life Sciences is a favorable investment for most analysts.

What is Kezar Life Sciences's price target?

Kezar Life Sciences's price target, set by 6 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $9 at the low end to $9 at the high end, suggesting a potential 87.89% change from the previous closing price of $4.79.

How does Kezar Life Sciences stock forecast compare to its benchmarks?

Kezar Life Sciences's stock forecast shows a 87.89% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Kezar Life Sciences over the past three months?

  • June 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Kezar Life Sciences’s EPS forecast?

Kezar Life Sciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-8.52, marking a 640.87% increase from the reported $-1.15 in 2024. Estimates for the following years are $-7.02 in 2026, $-7.86 in 2027, and $-6.26 in 2028.

What is Kezar Life Sciences’s revenue forecast?

Kezar Life Sciences's average annual revenue forecast for its fiscal year ending in December 2025 is $4M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $7M, followed by $21M for 2027, and $31.5M for 2028.

What is Kezar Life Sciences’s net income forecast?

Kezar Life Sciences's net income forecast for the fiscal year ending in December 2025 stands at $-542M, representing an 547.20% increase from the reported $-83.736M in 2024. Projections indicate $-563M in 2026, $-678M in 2027, and $-454M in 2028.